drug · small molecule
ponatinib hydrochloride
Marketedupdated 3mo agoby $TAK TAKEDA PHARMACEUTICAL CO LTD🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for acute lymphoblastic leukemia and chronic myelogenous leukemia and 4 investigational indications.
targets
Bcr/Abl fusion protein
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 22, 2026
123 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Dec 12, 2033method-of-use (U-1948)US 11192895
- Dec 12, 2033method-of-use (U-1948)US 11192895
- Dec 12, 2033method-of-use (U-1948)US 11192895
- Dec 12, 2033method-of-use (U-1948)US 11192895
- Dec 12, 2033compositionUS 11192897
- Dec 12, 2033compositionUS 11192897
- Dec 12, 2033compositionUS 11192897
- Dec 12, 2033compositionUS 11192897
- Dec 12, 2033compositionUS 11384086
- Dec 12, 2033compositionUS 11384086
- Dec 12, 2033compositionUS 11384086
- Dec 12, 2033compositionUS 11384086
- Dec 12, 2033compositionUS 9493470
- Dec 12, 2033compositionUS 9493470
- Dec 12, 2033compositionUS 9493470
- Dec 12, 2033compositionUS 9493470
- Jan 24, 2027compositionUS 8114874156d
- Jan 24, 2027compositionUS 8114874156d
- Jan 24, 2027compositionUS 8114874156d
- Jan 24, 2027compositionUS 8114874156d
- Dec 22, 2026method-of-use (U-1699)US 9029533123d
- Dec 22, 2026method-of-use (U-1699)US 9029533123d
- Dec 22, 2026method-of-use (U-1699)US 9029533123d
- Dec 22, 2026method-of-use (U-1283)US 9029533123d
FDA exclusivities (8)
- Mar 19, 2031ODE-472Orphan Drug (7y)4.6y
- Mar 19, 2031ODE-472Orphan Drug (7y)4.6y
- Mar 19, 2031ODE-472Orphan Drug (7y)4.6y
- Mar 19, 2031ODE-472Orphan Drug (7y)4.6y
- Mar 19, 2027I-934Indication (3y)210d
- Mar 19, 2027I-934Indication (3y)210d
- Mar 19, 2027I-934Indication (3y)210d
- Mar 19, 2027I-934Indication (3y)210d
News(1)
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that